WASHINGTON (AFP): Pharmaceutical company Merck said Friday (Oct 1) it will seek authorisation in the United States for an oral drug for Covid-19, after the pill showed "compelling results" in a clinical trial.
The experimental drug, molnupiravir, significantly reduced the risk of hospitalisation or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!